Immunochemotherapy pharmaceutical composition and preparation method therefor

Abstract

The invention discloses an immunochemotherapy pharmaceutical composition. The immunochemotherapy pharmaceutical composition is formed by mixing a first mixture with a second mixture; the first mixturecontains immunoadjuvant imiquimod R837; the second mixture contains chemotherapeutic drug oxaliplatin which can cause immunogenicity death, and further contains poloxamer 188 and sodium alginate (ALG); the first mixture is an imiquimod emulsion obtained by mixing the imiquimod R837 with the poloxamer 188; imiquimod particles each have a particle size of 0.5-3 mum; the imiquimod emulsion undergoesmoist heat sterilization; and the second mixture is a mixture prepared in a manner that the sodium alginate (ALG) and the oxaliplatin are stirred and mixed with water, and filtration sterilization isperformed with a micrometer filter membrane. The new anti-cancer pharmaceutical composition can exert the synergistic anticancer effect, reduces the side effect, the cancer metastasis probability andthe cancer recurrence probability, and can inhibit the growth of a distant metastatic tumor and reduce the tumor recurrence probability through the immunoreaction while effectively killing a tumor insitu; and meanwhile, the production process is relatively optimal, and the product stability is high.

Description

technical field [0001] The present invention relates to the field of drugs for treating tumors, in particular to a drug composition for combination therapy with chemotherapy and immunity, as well as a preparation method and application. Background technique [0002] Chemotherapy is one of the three main treatment methods for clinical treatment of tumors. Most cancer patients need to receive a certain degree of chemotherapy. For those tumors that have a tendency to metastasize or have metastasized, chemotherapy is the main treatment. However, traditional chemotherapy drugs can also damage normal organs, and the commonly used chemotherapy mode in clinic is systemic administration, which is not very selective for the lesion, and the side effects of chemotherapy are very serious. [0003] Although tumor immunotherapy represented by immune checkpoint blockade has made encouraging achievements in recent years, this therapy still has important limitations, including low clinical re...

AI Technical Summary

Problems solved by technology

However, traditional chemotherapy drugs can also damage normal organs, and the commonly used chemotherapy mode in clinic is systemic administration, which is not very selective for the lesion, and the side effects of chemotherapy are very serious

[0003] Although tumor immunotherapy represented by immune checkpoint blockade has made encouraging achievements in recent years, this therapy still has important limitations, including low clinical response rate (about 20%), non-specific immune response side effects, etc.

In particular, the low clinical response rate of current clinical immune checkpoint blockade therapy means that most patients do not respond to this expensive therapy

Images